Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Valneva SENASDAQ: VALN

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 31.1% from a year ago

Cash & equivalents stood at €105.37M at the end of Q1 FY2026, down 31.1% from a year earlier and down 3.9% from the prior quarter. Over 3 fiscal years it compounded at -27.6% a year.

Context

  • Cash & equivalents amounted to 28.3% of total assets at the end of Q1 FY2026, down 3.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -31.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
€105.37M-3.9% QoQ
Last fiscal yearDec 2025
€109.65M-34.8% YoY
Year agoMar 2025
€152.99M-31.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.1%——
1 year-34.8%——
3-year CAGR-27.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

EUR · from the balance sheet

Latest · FY2025
109.65M EUR
Year-over-year change
-34.8%
4-year CAGR
-25.0%

Cash & Equivalents vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -31.1% is the 6th highest of 8, against a peer median of -13.3%.
  • Cash & equivalents amounts to 28.3% of total assets for VALN, versus a peer median of 21.9%.
VALN Competitors
Cash & Equivalents for VALN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MRNAModerna, Inc.Sep 2026$1.2B USD+5.6%-6.8%8.9%
VIRVir Biotechnology, Inc.Mar 2026$276.09M USD+0.9%-34.9%26.9%
NVAXNovavax, Inc.Mar 2026$228.36M USD-13.3%-43.5%21.9%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$211.38M USD-2.6%-16.2%86.1%
PCVXVaxcyte, Inc.Jun 2026$183.19M USD-40.3%-40.7%5.8%
VALNValneva SEMar 2026€105.37M EUR-31.1%-27.6%28.3%
IBRXImmunityBio, Inc.Sep 2026$45.08M USD-25.2%-5.5%7.4%
INOInovio Pharmaceuticals, Inc.Mar 2026$26.27M USD-34.2%-1.5%52.8%
Peer median (excluding VALN) —-13.3%-16.2%21.9%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents346.64M289.43M126.08M168.27M109.65M
Short-term Investments00000
Net Receivables44.01M23.91M41.65M35.21M27.81M
Inventory124.1M35.1M44.47M53.66M50.23M
Other Current Assets71.04M76.21M50.63M41.87M34.85M
Total Current Assets585.83M424.66M262.82M299.01M222.54M
Property, Plant & Equipment (Net)173.83M154.04M156.59M158.12M138.03M
Goodwill00000
Intangible Assets32.7M28.71M25.57M25.26M22.35M
Long-term Investments2.12M0000
Tax Assets3.58M5.64M6.59M9.61M8.33M
Other Non-current Assets19.28M8.3M8.49M8.04M7.59M
Total Non-current Assets231.52M196.69M197.24M201.02M176.3M
Total Assets817.35M621.34M460.06M500.03M398.84M
Account Payables16.04M14.51M17.56M12.64M9.07M
Short-term Debt7.11M11.58M44.08M20.85M17.91M
Tax Payables83K16.27M632K8.09M6.91M
Deferred Revenue124.02M9.41M5.7M3.01M432K
Other Current Liabilities159.37M184.01M55.88M44.6M40.8M
Total Current Liabilities368.98M277.39M158.86M114.58M93.33M
Long-term Debt50.73M87.23M132.77M166.52M161.26M
Deferred Tax Liabilities1.29M694K3.64M4.16M4.41M
Deferred Revenue (Non-current)4.74M0000
Other Non-current Liabilities167.35M8.07M7.46M7.09M8.32M
Total Non-current Liabilities277.79M124.15M172.95M204.2M199.33M
Total Liabilities646.77M401.55M331.82M318.78M292.67M
Common Stock15.79M20.76M20.84M24.38M26.03M
Retained Earnings(306.97M)(450.25M)(551.68M)(563.93M)(679.12M)
Accumulated OCI52.51M55.25M65.73M40.15M40.74M
Other Stockholders Equity(646K)0033.7M43.22M
Minority Interest00000
Total Equity170.58M219.8M128.25M181.25M106.17M
Total Debt114.66M152.38M208.82M216.31M207.25M
Net Debt(231.99M)(137.05M)82.74M48.04M97.6M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.